Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yunlong Tan

Showing results (201-210 of 214) with videos related to

Pageof 22
Sort By:
The American Journal of Psychiatry|July 30, 2019
White Matter in Schizophrenia Treatment ResistancePeter Kochunov, Junchao Huang, Song Chen, et al.
Schizophrenia Bulletin|July 19, 2020
A White Matter Connection of Schizophrenia and Alzheimer's DiseasePeter Kochunov, Artemis Zavaliangos-Petropulu, Neda Jahanshad, et al.
Human Brain Mapping|May 29, 2020
Translating ENIGMA schizophrenia findings using the regional vulnerability index: Association with cognition, symptoms, and disease trajectoryPeter Kochunov, Fengmei Fan, Meghann C Ryan, et al.
JAMA Cardiology|November 16, 2017
Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese AdultsIona Y Millwood, Derrick A Bennett, Michael V Holmes, et al.
Alpha Psychiatry|May 11, 2026
Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World StudyWei Li, Jinghui Tong, Xiaoxiao Gao, et al.
BMC Psychiatry|April 6, 2026
Comparison of the effects of antipsychotic and combined with non-invasive brain stimulation on blood lipids in patients with schizophreniaGuangya Yang, Xue Yang, Hongbing Liu, et al.
Bjpsych Open|June 29, 2021
Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophreniaYi Su, Hao Yu, Zhiren Wang, et al.
Journal of Affective Disorders|February 22, 2023
A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorderQian Zhao, Bingbing Fu, Nan Lyu, et al.
Molecular Psychiatry|March 28, 2026
Brain structural abnormalities in treatment-resistant schizophreniaSemra Etyemez, Rohit Sivananthan, Andreia V Faria, et al.
Human Brain Mapping|April 18, 2020
ENIGMA-DTI: Translating reproducible white matter deficits into personalized vulnerability metrics in cross-diagnostic psychiatric researchPeter Kochunov, L Elliot Hong, Emily L Dennis, et al.
Pageof 22

Showing results (201-210 of 214) with videos related to

Sort By:
Pageof 22
The American Journal of Psychiatry|July 30, 2019
White Matter in Schizophrenia Treatment ResistancePeter Kochunov, Junchao Huang, Song Chen, et al.
Schizophrenia Bulletin|July 19, 2020
A White Matter Connection of Schizophrenia and Alzheimer's DiseasePeter Kochunov, Artemis Zavaliangos-Petropulu, Neda Jahanshad, et al.
Human Brain Mapping|May 29, 2020
Translating ENIGMA schizophrenia findings using the regional vulnerability index: Association with cognition, symptoms, and disease trajectoryPeter Kochunov, Fengmei Fan, Meghann C Ryan, et al.
JAMA Cardiology|November 16, 2017
Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese AdultsIona Y Millwood, Derrick A Bennett, Michael V Holmes, et al.
Alpha Psychiatry|May 11, 2026
Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World StudyWei Li, Jinghui Tong, Xiaoxiao Gao, et al.
BMC Psychiatry|April 6, 2026
Comparison of the effects of antipsychotic and combined with non-invasive brain stimulation on blood lipids in patients with schizophreniaGuangya Yang, Xue Yang, Hongbing Liu, et al.
Bjpsych Open|June 29, 2021
Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophreniaYi Su, Hao Yu, Zhiren Wang, et al.
Journal of Affective Disorders|February 22, 2023
A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorderQian Zhao, Bingbing Fu, Nan Lyu, et al.
Molecular Psychiatry|March 28, 2026
Brain structural abnormalities in treatment-resistant schizophreniaSemra Etyemez, Rohit Sivananthan, Andreia V Faria, et al.
Human Brain Mapping|April 18, 2020
ENIGMA-DTI: Translating reproducible white matter deficits into personalized vulnerability metrics in cross-diagnostic psychiatric researchPeter Kochunov, L Elliot Hong, Emily L Dennis, et al.
Pageof 22